FDA asking for more safety data on extended-release IPX203
The U.S. Food and Drug Administration (FDA) is asking for more information concerning the safety of  IPX203, an extended-release oral formulation of carbidopa and levodopa, before a final approval decision in treating Parkinson’s disease symptoms can be made. In a complete response letter to Amneal Pharmaceuticals,…